E. Ohman J or Asset Management AB Buys 10,506 Shares of Lantheus Holdings, Inc. $LNTH

E. Ohman J or Asset Management AB lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 56.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,238 shares of the medical equipment provider’s stock after acquiring an additional 10,506 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Lantheus were worth $1,500,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its holdings in Lantheus by 21.3% during the 3rd quarter. Pacer Advisors Inc. now owns 422,180 shares of the medical equipment provider’s stock worth $21,654,000 after purchasing an additional 74,272 shares during the last quarter. Milestone Asset Management LLC acquired a new stake in shares of Lantheus during the third quarter worth $762,000. World Investment Advisors bought a new position in Lantheus during the third quarter worth $280,000. Martin Capital Advisors LLP lifted its holdings in Lantheus by 3.2% in the third quarter. Martin Capital Advisors LLP now owns 12,978 shares of the medical equipment provider’s stock valued at $666,000 after buying an additional 405 shares during the period. Finally, Exchange Traded Concepts LLC boosted its position in Lantheus by 98.7% during the third quarter. Exchange Traded Concepts LLC now owns 15,994 shares of the medical equipment provider’s stock valued at $820,000 after acquiring an additional 7,943 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH opened at $66.71 on Friday. The firm has a market capitalization of $4.42 billion, a P/E ratio of 28.03 and a beta of -0.10. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The stock has a 50 day moving average price of $58.96 and a two-hundred day moving average price of $62.23.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LNTH shares. TD Cowen lowered their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. B. Riley cut their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Mizuho increased their price objective on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Truist Financial upped their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.